Therefore, the present study hypothesized that saroglitazar could modulate adipose tissue dysfunction, obesity-related inflammation, improve insulin sensitivity in MSG obese Wistar rats, and may prove an innovative therapeutic strategy to ameliorate obesity and associated co-morbidities. The gene discussed is INS; the disease is obesity disorder.